A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers

被引:26
作者
Farre, M [1 ]
Teran, MT [1 ]
Cami, J [1 ]
机构
[1] UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,DEPT PHARMACOL & TOXICOL,E-08003 BARCELONA,SPAIN
关键词
flunitrazepam; triazolam; performance; subject ratings; abuse liability;
D O I
10.1007/BF02247387
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Flunitrazepam is an hypnotic benzodiazepine marketed in different European countries. Epidemiological studies have shown that it is frequently abused by opioid addicts. In a survey, ''liking'' scores for flunitrazepam in methadone maintenance patients were higher than ratings for other benzodiazepines. A double-blind, placebo controlled, crossover clinical trial was conducted to assess the acute behavioral effects of flunitrazepam (0.50 and 2 mg) and triazolam (0.25 and 0.50 mg) in healthy male volunteers. Drug effects on physiological measures, psychomotor performance, and subjective rating scales, including specific questionnaires to evaluate abuse liability (e.g., ARCI or ''liking'' scores), were assessed before and 6 h after drug administration. Flunitrazepam 2 mg produced the most intense disruptive effects on all the performance tasks, triazolam 0.50 impaired performance except balance. All study drugs at all doses produced sedation symptoms in all or part of the subjective effects questionnaires. Only flunitrazepam 2 mg induced significative increases in some of the scales (''liking'', ''good effects'', ''high'') that could be related to a possible abuse potential. The results seem to indicate that flunitrazepam, when administered to healthy subjects, produces some pleasurable subjective feelings, that could indicate a higher abuse liability of this drug as compared with other benzodiazepines.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 47 条
[1]  
ARENDT RM, 1983, J PHARMACOL EXP THER, V227, P98
[2]  
*ASS BRIT PHARM IN, 1994, DAT SHEET COMP
[3]  
BALTER MB, 1984, CURR MED RES OPIN, V8, P5
[4]  
BARNAS C, 1992, J CLIN PSYCHOPHARM, V12, P397
[5]  
BERLIN I, 1993, J CLIN PSYCHOPHARM, V13, P100
[6]   SYSTEMIC ABSORPTION AND ABUSE LIABILITY OF SNORTED FLUNITRAZEPAM [J].
BOND, A ;
SEIJAS, D ;
DAWLING, S ;
LADER, M .
ADDICTION, 1994, 89 (07) :821-830
[7]  
CAPPELL H, 1987, PSYCHOPHARMACOLOGY, V91, P154
[8]   TESTING THE ABUSE LIABILITY OF ANXIOLYTIC AND HYPNOTIC DRUGS IN HUMANS [J].
DEWIT, H ;
GRIFFITHS, RR .
DRUG AND ALCOHOL DEPENDENCE, 1991, 28 (01) :83-111
[9]   REINFORCING PROPERTIES OF LORAZEPAM IN NORMAL VOLUNTEERS [J].
DEWIT, H ;
JOHANSON, CE ;
UHLENHUTH, EH .
DRUG AND ALCOHOL DEPENDENCE, 1984, 13 (01) :31-41
[10]  
Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1